Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

gutMAP

Financiado

Gut microbiome-mediated activities of psychotropic drugs

Mental illnesses are among the most prevalent health burdens, with major depression ranking fourth among the leading causes of disease worldwide. Although diverse psychotropic drugs are available, the delayed onset of drug action,... ver más

31/12/2028

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-01-19

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-STG: ERC STARTING GRANTS

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

1.50M€ | Lider

Proyectos interesantes

DREAM The pharmaco-microbiomics of depression 217K€ Cerrado

CNS2023-144218 Fisiopatología de órganos y sistemas 200K€ Cerrado

PID2021-126468OA-I00 INVESTIGACION DE LA INTERACCION ORAL-INTESTINAL-CEREBRAL EN... 97K€ Cerrado

BiPMeM Mechanistic study of gut microbial biotransformation reactio... 174K€ Cerrado

MicroBED The Influence of Gut Microbiota and Microbial Metabolites on... 201K€ Cerrado

AGL2017-88801-P IDENTIFICACION DE ESTRATEGIAS DE INTERVENCION BASADAS EN EL... 224K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 71 meses Fecha Inicio: 2023-01-19
Fecha Fin: 2028-12-31

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto Mental illnesses are among the most prevalent health burdens, with major depression ranking fourth among the leading causes of disease worldwide. Although diverse psychotropic drugs are available, the delayed onset of drug action, high non-responder rates and frequent side effects still pose significant challenges. Several observations suggest the gut microbiome as major contributor to high inter-individual differences in drug responses. While there is evidence that these drugs lead to changes in the microbiome composition of patients, it has not yet been explored whether these effects are part of the drug mode of action and/or whether they contribute to side effects. The aim of this project is to investigate to what extent gut microbes are involved in the therapeutic outcome of psychotropic drugs by employing model synthetic and patient derived microbiome communities (from stool of drug responders, non-responders and healthy controls), and in vivo gnotobiotic mouse models. We will systematically characterize the reciprocal interactions between gut microbes and commonly used psychotropic drugs ex vivo – from microbial drug metabolism to drug-induced bacterial secretion of neuroactive compounds. For intriguing interactions, we will elucidate the underlying mechanisms and use the knowledge to design engineered microbiomes. We will then employ gnotobiotic knockout mice deficient for primary drug targets of psychotropic drugs and colonize them with microbiome communities carrying the different mapped traits to separate the contribution of drug effects originating from the microbiome from those of the host. Overall, our results will inform microbiome-guided therapeutic strategies whose improved efficacy we will test in vivo. Due to the transferability of the developed technology and if successful, this new research direction could not only revolutionize psychotropic drug therapy, but also pave new ways for improving personalized drug therapy for many other diseases.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores